Serum elabela and apelin levels during different stages of chronic kidney disease

References

• Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.
   PubMed Web of Science ®Google Scholar
• Collister D, Ferguson T, Komenda P, et al. The patterns, risk factors, and prediction of progression in chronic kidney disease: a narrative review. Semin Nephrol. 2016;36(4):273–282.
   PubMed Web of Science ®Google Scholar
• Ju W, Smith S, Kretzler M. Genomic biomarkers for chronic kidney disease. Transl Res. 2012;159(4):290–302.
   PubMed Web of Science ®Google Scholar
• O'Carroll AM, Lolait SJ, Harris LE, et al. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol. 2013;219(1):R13–35.
   PubMed Web of Science ®Google Scholar
• Azizi M, Iturrioz X, Blanchard A, et al. Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol. 2008;19(5):1015–1024.
   PubMed Web of Science ®Google Scholar
• El Messari S, Iturrioz X, Fassot C, et al. Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. J Neurochem. 2004;90(6):1290–1301.
   PubMed Web of Science ®Google Scholar
• Pitkin SL, Maguire JJ, Bonner TI, et al. International union of basic and clinical pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62(3):331–342.
   PubMed Web of Science ®Google Scholar
• Masri B, Knibiehler B, Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal. 2005;17(4):415–426.
   PubMed Web of Science ®Google Scholar
• Chapman NA, Dupre DJ, Rainey JK. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. Biochem Cell Biol. 2014;92(6):431–440.
   PubMedGoogle Scholar
• Knauf C, Drougard A, Fournel A, et al. Hypothalamic actions of apelin on energy metabolism: new insight on glucose homeostasis and metabolic disorders. Horm Metab Res. 2013;45(13):928–934.
   PubMed Web of Science ®Google Scholar
• Lacquaniti A, Chirico V, Lupica R, et al. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease. Peptides. 2013;49:1–8.
   PubMed Web of Science ®Google Scholar
• Szczepańska M, Machura E, Adamczyk P, et al. Evaluation of adipocytokines in children with chronic kidney disease. Endokrynol Pol. 2015;66(2):100–107.
   PubMed Web of Science ®Google Scholar
• Zhang BH, Wang W, Wang H, et al. Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One. 2013;8(4):e60457.
   PubMed Web of Science ®Google Scholar
• Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol. 2013;304(6):F788–800.
   PubMed Web of Science ®Google Scholar
• Chng SC, Ho L, Tian J, et al. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013;27(6):672–680.
   PubMed Web of Science ®Google Scholar
• Pauli A, Norris ML, Valen E, et al. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science. 2014;343(6172):1248636.
   PubMed Web of Science ®Google Scholar
• Charo DN, Ho M, Fajardo G, et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol. 2009;297(5):H1904–1913.
   PubMed Web of Science ®Google Scholar
• Scott IC, Masri B, D'Amico LA, et al. The g protein-coupled receptor agtrl1b regulates early development of myocardial progenitors. Dev Cell. 2007;12(3):403–413.
   PubMed Web of Science ®Google Scholar
• Deng C, Chen H, Yang N, et al. Apela regulates fluid homeostasis by binding to the APJ receptor to activate Gi signaling. J Biol Chem. 2015;290(30):18261–18268.
   PubMed Web of Science ®Google Scholar
• Wang G, Anini Y, Wei W, et al. Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology. 2004;145(3):1342–1348.
   PubMed Web of Science ®Google Scholar
• Schreiber CA, Holditch SJ, Generous A, et al. Sustained ELABELA gene therapy in high-salt diet-induced hypertensive rats. Curr Gene Ther. 2017;16(5):349–360.
   PubMed Web of Science ®Google Scholar
• National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266.
   PubMed Web of Science ®Google Scholar
• Kirkendall WM, Feinleib M, Freis ED, et al. Recommendations for human blood pressure determination by sphygmomanometers. Subcommittee of the AHA Postgraduate Education Committee. Hypertension. 1981;3(4):510A–519A.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wu L, Chen L. Apelin/APJ system: a novel potential therapy target for kidney disease. J Cell Physiol. 2018;233(5):3892–3900.
   PubMed Web of Science ®Google Scholar
• Murza A, Sainsily X, Coquerel D, et al. Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J Med Chem. 2016;59(7):2962–2972.
   PubMed Web of Science ®Google Scholar
• Hus-Citharel A, Bodineau L, Frugiere A, et al. Apelin counteracts vasopressin-induced water reabsorption via cross talk between apelin and vasopressin receptor signaling pathways in the rat collecting duct. Endocrinology. 2014;155(11):4483–4493.
   PubMed Web of Science ®Google Scholar
• Xie F, Lv D, Chen L. ELABELA: a novel hormone in cardiac development acting as a new endogenous ligand for the APJ receptor. Acta Biochim Biophys Sin. 2014;46(7):620–622.
   Google Scholar
• Ho L, Tan SY, Wee S, et al. ELABELA is an endogenous growth factor that sustains hESC self-renewal via the PI3K/AKT pathway. Cell Stem Cell. 2015;17(4):435–447.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yu D, Wang M, Wang Q, et al. Elabela-apelin receptor signaling pathway is functional in mammalian systems. Sci Rep. 2015;5:8170.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Lou Y, et al. Elabela, a newly discovered APJ ligand: similarities and differences with Apelin. Peptides. 2018;109:23–32.
   PubMed Web of Science ®Google Scholar
• Sun X, Yuan X, Chen L, et al. Histamine induces bovine rumen epithelial cell inflammatory response via NF-κB pathway. Cell Physiol Biochem. 2017;42(3):1109–1119.
   PubMedGoogle Scholar
• Masaki Goto NDV, Park C, Streja E, et al. Advanced chronic kidney disease is associated with significant serum elabela levels: potencial correlation with uremic cardiomyopathy. Circulation. 2018;138:A14939.
   Web of Science ®Google Scholar
• Perjes A, Kilpio T, Ulvila J, et al. Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. Basic Res Cardiol. 2016;111(1):2.
   PubMed Web of Science ®Google Scholar
• Yang P, Maguire JJ, Davenport AP. Apelin, elabela/toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci. 2015;36(9):560–567.
   PubMed Web of Science ®Google Scholar
• Yang P, Read C, Kuc RE, et al. Elabela/toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation. 2017;135(12):1160–1173.
   PubMed Web of Science ®Google Scholar
• Ho L, van Dijk M, Chye STJ, et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice. Science. 2017;357(6352):707–713.
   PubMed Web of Science ®Google Scholar
• Coquerel D, Chagnon F, Sainsily X, et al. ELABELA improves cardio-renal outcome in fatal experimental septic shock. Crit Care Med. 2017;45(11):e1139–e1148.
   PubMed Web of Science ®Google Scholar